### PCT

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7:	A2	(11) International Publication Number:	WO 00/10552
A61K 31/00		(43) International Publication Date:	2 March 2000 (02.03.00)

(21) International Application Number: PCT/US99/19218

(22) International Filing Date: 24 August 1999 (24.08.99)

(30) Priority Data: 60/097,579

24 August 1998 (24.08.98) U

(71) Applicant: GLOBAL VASCULAR CONCEPTS, INC. [US/US]; 4615 Brookhollow Road, Atlanta, GA 30327 (US).


(72) Inventors: BROWN, Charles, L., Ill; 4615 Brookhollow Road, Atlanta, GA 30327 (US). GORLIN, Steve; 150 Gulf Shore Drive, Destin, FL 32541 (US).

(74) Agents: WARREN, William, L. et al.; Jones & Askew, LLP, 2400 Monarch Tower, 3424 Peachtree Road, Atlanta, GA 30326 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SI, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published

Without international search report and to be republished upon receipt of that report.

(54) Title: USE OF ANTI-ANGIOGENIC AGENTS FOR INHIBITING VESSEL WALL INJURY



### (57) Abstract

Use of anti-angiogenic agents to inhibit an undesireable response to vessel wall injury, including stent neointima, dialysis graft neointima, vascular graft induced neointima, and the treatment of benign hypertrophic scar formation as well as the treatment and passivation of unstable atherosclerotic plaques are provided. The invention provides for the use of cathetes-based devices for enhancing the local delivery of anti-angiogenic agents into the endothelial tissues of blood vessels of the living body.